Clinical Development


Onyx is developing oprozomib, a novel oral proteasome inhibitor. Oprozomib is distinct from carfilzomib, although the compound is based on the same chemistry that is employed to selectively target the proteasome. Oprozomib is being developed as an oral therapy and is currently being studied in a number of trials, including a Phase 1b/2 study evaluating oprozomib in hematologic malignancies including multiple myeloma and a Phase 1 study in patients with recurrent or refractory solid tumors.